Repligen Corporation reports business developments as a global life sciences company focused on bioprocessing technologies and systems used in manufacturing biological drugs. Its updates center on Filtration and Fluid Management, Chromatography, Process Analytics and Proteins, serving biopharmaceutical drug developers, CDMOs and other life science customers.
Recurring announcements include quarterly and annual financial results, financial guidance, organic revenue measures, margin commentary, product and support infrastructure such as Repligen Training & Innovation Centers and OPUS pre-packed chromatography columns, investor conference participation, regional customer support initiatives and board or senior finance governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Repligen Corporation (NASDAQ:RGEN) will announce its first quarter 2023 financial results on May 2, 2023, before the market opens. A conference call is scheduled for 8:30 a.m. ET to discuss business updates and financial results for the quarter ending March 31, 2023. Investors can join the call by dialing (844) 274-3999 (U.S.) or (412) 317-5607 (international) without a passcode. A webcast will also be available on the Company’s Investor Relations page. Repligen specializes in bioprocessing technologies for biopharmaceutical manufacturing.
Repligen Corporation (NASDAQ:RGEN) announced its participation in the KeyBanc Life Science and MedTech Investor Forum on March 21-22, 2023. CEO Tony J. Hunt will lead an analyst-led discussion on March 21 at 1:30 p.m. EDT. A live webcast of the presentation will be available on the Company's Investor Relations website and will be accessible for replay after the event. Repligen specializes in bioprocessing technologies, aiming to improve the manufacturing efficiency of biological drugs for biopharmaceutical developers and contract organizations globally. The company operates in various locations, primarily within the U.S., and has a strong presence in multiple European countries.
Repligen Corporation (NASDAQ:RGEN) reported strong financial results for the fourth quarter and full year 2022. Fourth quarter revenue reached $186.8 million, marking 4% organic growth year-over-year, while full-year revenue totaled $801.5 million, a 22% organic growth. The base business demonstrated impressive organic growth of 35% in Q4 and 39% for the year. Despite these achievements, gross profit decreased in Q4 by 9%, impacted by declining COVID-related product revenues and increased costs. Looking ahead, Repligen expects 2023 total revenue between $760-$800 million, anticipating a reduction in COVID-related revenue and gross margin decline to 52.5%-53.5%.
Repligen Corporation (NASDAQ:RGEN) has appointed Martin D. Madaus to its Board of Directors, enhancing its leadership in the bioprocessing sector. Dr. Madaus brings over 25 years of experience, notably transforming Millipore Corporation into a life sciences leader before its acquisition by Merck KGaA. He currently serves on the boards of multiple public and private companies and will leverage his expertise in strategy and commercial operations to support Repligen's growth and innovation. Company leadership expresses confidence in his contributions towards expanding their product portfolio and market presence.